100 Recruiting Studies Using Venetoclax
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Venetoclax
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
📍 Banner MD Anderson — Gilbert, Arizona
Leukemia, Myeloid, Acute
View Study & Checklist ➔The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
📍 Stanford University Medical Center (Data collection only) — Stanford, California
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Recurrent Mantle Cell Lymphoma
View Study & Checklist ➔A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
📍 City of Hope /ID# 154105 — Duarte, California
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
📍 University of Colorado Cancer Center — Aurora, Colorado
Cancer
View Study & Checklist ➔A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
📍 City of Hope National Medical Center — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
📍 City of Hope Medical Center — Duarte, California
B Acute Lymphoblastic Leukemia
View Study & Checklist ➔Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
📍 City of Hope Medical Center — Duarte, California
Recurrent Acute Myeloid Leukemia
View Study & Checklist ➔Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Acute Biphenotypic Leukemia
View Study & Checklist ➔Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
📍 Beth Israel Deaconness Medical — Boston, Massachusetts
Waldenstrom Macroglobulinemia
View Study & Checklist ➔Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
View Study & Checklist ➔Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
📍 Memorial Sloan Kettering Basking Ridge (All protocol activities) — Basking Ridge, New Jersey
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
📍 University of Alabama at Birmingham - Main /ID# 151405 — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
📍 University of Chicago — Chicago, Illinois
Leukemia
View Study & Checklist ➔GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Mantle Cell Lymphoma
View Study & Checklist ➔IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
📍 City of Hope National Medical Center /ID# 269273 — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
📍 City of Hope — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
📍 Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407 — Tucson, Arizona
Multiple Myeloma
View Study & Checklist ➔Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
📍 City of Hope — Duarte, California
Leukemia, Myeloid, Acute
View Study & Checklist ➔A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
📍 City of Hope Cancer Center (Data collection only) — Duarte, California
Marginal Zone Lymphoma
View Study & Checklist ➔A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
📍 Univ of Colorado Cancer Center /ID# 167331 — Aurora, Colorado
Multiple Myeloma
View Study & Checklist ➔Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
📍 Research Site — Los Angeles, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
📍 Boston Medical Center — Boston, Massachusetts
AL Amyloidosis
View Study & Checklist ➔Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
📍 University of California, Los Angeles — Los Angeles, California
Acute Myeloid Leukemia
View Study & Checklist ➔Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Mantle Cell Lymphoma
View Study & Checklist ➔A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
📍 City of Hope Nat'l Medical Center — Duarte, California
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
📍 Washington University School of Medicine, Siteman Cancer Center — St Louis, Missouri
Diffuse Large B-cell-lymphoma
View Study & Checklist ➔Safe Accelerated Venetoclax Escalation in CLL
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
📍 The University of Alabama at Birmingham — Birmingham, Alabama
Leukemia, Myeloid, Acute
View Study & Checklist ➔Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Secondary Myelodysplastic Syndrome
View Study & Checklist ➔Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
📍 City of Hope National Medical Center — Duarte, California
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
📍 O'Neal Comprehensive Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax Plus Inotuzumab for B-ALL
📍 Brigham and Women's Hospital — Boston, Massachusetts
B-cell Acute Lymphoblastic Leukemia
View Study & Checklist ➔BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
📍 Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
📍 University of Chicago — Chicago, Illinois
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Lymphoma
View Study & Checklist ➔A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
📍 Research Site — Hackensack, New Jersey
Mantle Cell Lymphoma (MCL)
View Study & Checklist ➔Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
📍 MD Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Recurrent Adult Lymphoblastic Lymphoma
View Study & Checklist ➔Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
📍 Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔Copanlisib Plus Venetoclax in R/R DLBCL
📍 City of Hope Cancer Center — Duarte, California
Diffuse Large B Cell Lymphoma
View Study & Checklist ➔Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
📍 Brigham and Women's Hospital — Boston, Massachusetts
Myeloid Malignancy
View Study & Checklist ➔Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
📍 Rady Children's Hospital-San Diego — San Diego, California
Acute Leukemia of Ambiguous Lineage in Relapse
View Study & Checklist ➔Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Recurrent AL Amyloidosis
View Study & Checklist ➔A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Richter Syndrome
View Study & Checklist ➔Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
📍 Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
Relapsed Non Hodgkin Lymphoma
View Study & Checklist ➔Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
📍 Alaska Oncology and Hematology, Llc — Anchorage, Alaska
CLL
View Study & Checklist ➔AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia in Remission
View Study & Checklist ➔Cladribine Venetoclax in Monocytic AML
📍 Universtiy of Colorado Hospital — Aurora, Colorado
Acute Myeloid Leukemia
View Study & Checklist ➔A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
📍 Ironwood Physicians, Ironwood Cancer and Research Centers — Chandler, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
📍 BCCA - Vancouver — Vancouver, British Columbia
Lymphoma, B-Cell
View Study & Checklist ➔MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Multiple Myeloma
View Study & Checklist ➔Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
📍 Emory University — Atlanta, Georgia
B-Cell Lymphoma, Unspecified
View Study & Checklist ➔A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Acute Lymphoblastic Leukemia
View Study & Checklist ➔Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
📍 UC San Diego Moores Cancer Center — La Jolla, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
📍 Oregon Health Sciences University — Portland, Oregon
Myelodysplastic Syndromes
View Study & Checklist ➔Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
📍 University of Arizona Cancer Center - Tucson /ID# 210548 — Tucson, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
📍 Augusta University — Augusta, Georgia
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
View Study & Checklist ➔Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
📍 OHSU Knight Cancer Institute — Portland, Oregon
B Acute Lymphoblastic Leukemia
View Study & Checklist ➔Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
📍 University of Miami- Sylvester Comprehensive Cancer Center — Miami, Florida
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
CCND1 Positive
View Study & Checklist ➔Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Blastoid Variant Mantle Cell Lymphoma
View Study & Checklist ➔Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
📍 Duplicate_Providence Medical Foundation /ID# 222633 — Fullerton, California
Myelodysplastic Syndrome (MDS)
View Study & Checklist ➔Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
📍 The Oncology Institute Clinical Research — Cerritos, California
Leukemia, Lymphocytic, Chronic, B-Cell
View Study & Checklist ➔Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
📍 University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Recurrent Plasma Cell Myeloma
View Study & Checklist ➔Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
📍 UCSD Koman Family Outpatient Pavilion — San Diego, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Pilot Study of Reduced Venetoclax Exposure
📍 Zuckerberg Cancer Center — New Hyde Park, New York
Acute Myeloid Leukemia in Remission
View Study & Checklist ➔Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Refractory Acute Lymphoblastic Leukemia
View Study & Checklist ➔Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
📍 O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham — Birmingham, Alabama
Relapsed/Refractory Chronic Lymphocytic Leukemia
View Study & Checklist ➔Ibrutinib + Venetoclax in Untreated WM
📍 Massachusetts General Hospital — Boston, Massachusetts
Waldenstrom Macroglobulinemia
View Study & Checklist ➔An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
📍 Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
Recurrent B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 Research Site — Tucson, Arizona
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
View Study & Checklist ➔Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
📍 Weill Cornell Medicine/NewYork-Presberteryian Hospital — New York, New York
Leukemia, Lymphocytic, Chronic, B-Cell
View Study & Checklist ➔Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
📍 M D Anderson Cancer Center — Houston, Texas
Acute Bilineal Leukemia
View Study & Checklist ➔A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
📍 Georgetown University Medical Center — Washington D.C., District of Columbia
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
📍 University of California, San Francisco (UCSF) Fresno — Fresno, California
Ann Arbor Stage II Follicular Lymphoma
View Study & Checklist ➔A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
📍 Highlands Oncology Group — Springdale, Arkansas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
📍 Arizona Oncology - Tucson - Wilmot Road /ID# 252351 — Tucson, Arizona
Hematologic Cancer
View Study & Checklist ➔A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Norton Cancer Institute — Louisville, Kentucky
Leukemia, Lymphocytic, Chronic, B-Cell
View Study & Checklist ➔Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
📍 Roswell Park Comprehensive Cancer Center — Buffalo, New York
Myeloproliferative Neoplasm
View Study & Checklist ➔Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
📍 Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Chronic Lymphocytic Leukemia
View Study & Checklist ➔